Latest News

narcolepsy
The Role of Orexin Receptor 2 Agonists in Sleep and Narcolepsy Type 1

February 15th 2024

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

sleep
Positive Data on Oral Orexin Receptor 2 Agonist for Patients with Narcolepsy Type 1

February 9th 2024

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.
The Week in Review: January 29-February 2

February 3rd 2024

Here’s how we can help improve quality of sleep in both our patients and ourselves.
Get Cozy and Keep Sleeping

January 31st 2024

What is new in research on sleep?
Sleep Research Roundup: January 12, 2024

January 12th 2024

Video Interviews
Podcasts
Latest CME Events & Activities

The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease

View More

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia

View More

Advances In™ Schizophrenia: Expanding the Therapeutic Landscape

View More

Southern California Psychiatry Conference

September 13-14, 2024

Register Now!

Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder

View More

5th Annual International Congress on the Future of Neurology®

View More

2023 Annual Psychiatric Times™ World CME Conference

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.